Nanotechnology for cancer treatment

Nanotechnology Reviews

Volumn 3, Issue 2, 2014, Pages 111-122

  Gmeiner, William H ^a   Ghosh, Supratim ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Drug delivery; Nanotechnology

Indexed keywords

CELL DEATH; CONTROLLED DRUG DELIVERY; DISEASES; DRUG DELIVERY; NANOTECHNOLOGY;

BIOLOGICAL APPROACH; CANCER; CANCER CELLS; NANO SCALE; PASSIVE TARGETING;

TARGETED DRUG DELIVERY;

EID: 84926480881     PISSN: 21919089     EISSN: 21919097     Source Type: Journal    
DOI: 10.1515/ntrev-2013-0013     Document Type: Article

References (129)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893-2917
2. Barnard RJ. Prevention of cancer through lifestyle changes. Evid. Based Complementary Altern. Med. 2004, 1, 233-239
3. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin. Radiat. Oncol. 2007, 17, 2-9
4. Watabe K, Nishi M, Miyake H, Hirata K. Lifestyle and gastric cancer: a case-control study. Oncol. Rep. 1998, 5, 1191-1194
5. Moniz M, Ling M, Hung CF, Wu TC. HPV DNA vaccines. Front. Biosci. 2003, 8, d55-d68
6. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006, 24 Suppl 3, S3/11-25
7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189, 12-19
8. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374, 301-314
9. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabar L, Larsson L-G. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 1993, 341, 973-978
10. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003, 124, 544-560
11. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41, 189-207
12. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control. Release 2012, 164, 138-144
13. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 2008, 60, 1615-1626
14. Hongmei Li SSY, Miteva M, Nelson CE, Werfel T, Giorgio TD, Duvall, CL. Matrix metalloproteinase responsive, proximityactivated polymeric nanoparticles for siRNA delivery. Adv. Funct. Mater. 2013, 23, 3040-3052
15. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond) 2010, 5, 523-528
16. Shchors K, Evan G. Tumor angiogenesis: cause or consequence of cancer? Cancer Res. 2007, 67, 7059-7061
17. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 2011, 17, 1359-1370
18. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012, 2, 3-44
19. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 2010, 21, 797-802
20. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol. Cancer Ther. 2009, 8, 2861-2871
21. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Method Enzymol: Protein Engineering for Therapeutics Vol203, Pt B. 2012, 503, 255-268
22. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, Dai H. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008, 68, 6652-6660
23. Robinson JT, Hong G, Liang Y, Zhang B, Yaghi OK, Dai H. In vivo fluorescence imaging in the second near-infrared window with long circulating carbon nanotubes capable of ultrahigh tumor uptake. J. Am. Chem. Soc. 2012, 134, 10664-10669
24. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv. Drug Deliv. Rev. 2011, 63, 161-169
25. Wen AM, Shukla S, Saxena P, Aljabali AA, Yildiz I, Dey S, Mealy JE, Yang AC, Evans DJ, Lomonossoff GP, Steinmetz NF. Interior engineering of a viral nanoparticle and its tumor homing properties. Biomacromolecules 2012, 13, 3990-4001
26. Gormley AJ, Larson N, Sadekar S, Robinson R, Ray A, Ghandehari H. Guided delivery of polymer therapeutics using plasmonic photothermal therapy. Nano Today 2012, 7, 158-167
27. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148, 135-146
28. Mail JL, Raki M, Bergström KA, Uutela P, Lehtinen K, Hiltunen A, Pikkarainen J, Liang H, Pitkänen S, Määttä A-M, Ketola RA, Yliperttula M, Wirth T, Urtti A. Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma PLoS One 2012, 7, e41410
29. Yang L, Mao H, Wang YA, Cao Z, Peng X, Wang X, Duan H, Ni C, Yuan Q, Adams G, Smith MQ, Wood WC, Gao X, Nie S. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 2009, 5, 235-243
30. Choi CH, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natl. Acad. Sci. USA 2010, 107, 1235-1240
31. Huang RK, Steinmetz NF, Fu CY, Manchester M, Johnson JE. Transferrin-mediated targeting of bacteriophage HK97 nanoparticles into tumor cells. Nanomedicine (Lond.) 2011, 6, 55-68
32. Ishida O, Maruyama K. Transferrin conjugated PEG-liposomes as intracellular targeting carrier for tumor therapy. Nihon Rinsho 1998, 56, 657-662
33. Li JL, Wang L, Liu XY, Zhang ZP, Guo HC, Liu WM, Tang SH. In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles. Cancer Lett. 2009, 274, 319-326
34. Fay F, McLaughlin KM, Small DM, Fennell DA, Johnston PG, Longley DB, Scott CJ. Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery. Biomaterials 2011, 32, 8645-8653
35. Ding B, Wu X, Fan W, Wu Z, Gao J, Zhang W, Ma L, Xiang W, Zhu Q, Liu J, Ding X, Gao S. Anti-DR5 monoclonal antibodymediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. Int. J. Nanomed. 2011, 6, 1991-2005
36. Dixit V, Van den Bossche J, Sherman DM, Thompson DH, Andres RP. Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjug. Chem. 2006, 17, 603-609.
37. Esmaeili F, Ghahremani MH, Ostad SN, Atyabi F, Seyedabadi M, Malekshahi MR, Amini M, Dinarvand R. Folate-receptortargeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J. Drug Target. 2008, 16, 415-423
38. Kularatne SA, Low PS. Targeting of nanoparticles: folate receptor. Methods Mol. Biol. 2010, 624, 249-265
39. Schroeder JE, Shweky I, Shmeeda H, Banin U, Gabizon A. Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles. J. Control. Release 2007, 124, 28-34
40. Song EQ, Zhang ZL, Luo QY, Lu W, Shi YB, Pang DW. Tumor cell targeting using folate-conjugated fluorescent quantum dots and receptor-mediated endocytosis. Clin. Chem. 2009, 55, 955-963
41. Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 2012, 4, 128ra39
42. Kasten BB, Liu T, Nedrow-Byers JR, Benny PD, Berkman CE. Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorg. Med. Chem. Lett. 2013, 23, 565-568
43. El-Sayed IH, Huang X, El-Sayed MA. Selective laser photothermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 2006, 239, 129-35
44. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 2006, 103, 6315-6320
45. Yu C, Hu Y, Duan J, Yuan W, Wang C, Xu H, Yang XD. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One 2011, 6, e24077
46. Singh R, Erickson HK. Antibody-cytotoxic agent conjugates: preparation and characterization. Methods Mol. Biol. 2009, 525, 445-467, xiv
47. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond.) 2011, 6, 715-728
48. Romberg B, Hennink WE, Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 2008, 25, 55-71
49. Schipper ML, Iyer G, Koh AL, Cheng Z, Ebenstein Y, Aharoni A, Keren S, Bentolila LA, Li J, Rao J, Chen X, Banin U, Wu AM, Sinclair R, Weiss S, Gambhir SS. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 2009, 5, 126-134
50. Shah NB, Vercellotti GM, White JG, Fegan A, Wagner CR, Bischof JC. Blood-nanoparticle interactions and in vivo biodistribution: impact of surface PEG and ligand properties. Mol. Pharm. 2012, 9, 2146-2155
51. Xiao K, Li Y, Luo J, Lee JS, Xiao W, Gonik AM, Agarwal RG, Lam KS. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 2011, 32, 3435-3446
52. Amoozgar Z, Park J, Lin Q, Yeo Y. Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery. Mol. Pharm. 2012, 9, 1262-1270
53. Minchin RF, Martin DJ. Nanoparticles for molecular imaging-an overview. Endocrinology 2010, 151, 474-481
54. Islam T, Harisinghani MG. Overview of nanoparticle use in cancer imaging. Cancer Biomark. 2009, 5, 61-67
55. Will O, Purkayastha S, Chan C, Athanasiou T, Darzi AW, Gedroyc W, Tekkis PP. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol. 2006, 7, 52-60
56. Peng XH, Qian X, Mao H, Wang AY, Chen ZG, Nie S, Shin DM. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int. J. Nanomed. 2008, 3, 311-321
57. Yang L, Peng XH, Wang YA, Wang X, Cao Z, Ni C, Karna P, Zhang X, Wood WC, Gao X, Nie S, Mao H. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin. Cancer Res. 2009, 15, 4722-4732
58. Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, Chen H, Wu X, Mao H. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 2010, 70, 6303-6312
59. Xie J, Liu G, Eden HS, Ai H, Chen X. Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc. Chem. Res. 2011, 44, 883-892
60. Perrault SD, Chan WC. In vivo assembly of nanoparticle components to improve targeted cancer imaging. Proc. Natl. Acad. Sci. USA 2010, 107, 11194-11199
61. Bogdanov A, Jr, Mazzanti ML. Molecular magnetic resonance contrast agents for the detection of cancer: past and present. Semin. Oncol. 2011, 38, 42-54
62. Bogdanov A, Jr, Matuszewski L, Bremer C, Petrovsky A, Weissleder R. Oligomerization of paramagnetic substrates result in signal amplification and can be used for MR imaging of molecular targets. Mol. Imaging 2002, 1, 16-23
63. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new X-ray contrast agent. Br. J. Radiol. 2006, 79, 248-253
64. Chithrani DB, Dunne M, Stewart J, Allen C, Jaffray DA. Cellular uptake and transport of gold nanoparticles incorporated in a liposomal carrier. Nanomedicine 2010, 6, 161-169
65. Chithrani DB, Jelveh S, Jalali F, van Prooijen M, Allen C, Bristow RG, Hill RP, Jaffray DA. Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat. Res. 2010, 173, 719-728
66. Ahmed N, Fessi H, Elaissari A. Theranostic applications of nanoparticles in cancer. Drug Discov. Today. 2012, 17, 928-934
67. Smith L, Kuncic Z, Ostrikov K, Kumar S. Nanoparticles in cancer imaging and therapy. J. Nanomater. 2012, 2012, 1-7
68. Yoo D, Lee JH, Shin TH, Cheon J. Theranostic magnetic nanoparticles. Acc. Chem. Res. 2011, 44, 863-874
69. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv. Drug Deliv. Rev. 2010, 62, 1064-1079
70. Kohler N, Sun C, Wang J, Zhang M. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 2005, 21, 8858-8864
71. Hwu JR, Lin YS, Josephrajan T, Hsu MH, Cheng FY, Yeh CS, Su WC, Shieh DB. Targeted paclitaxel by conjugation to iron oxide and gold nanoparticles. J. Am. Chem. Soc. 2009, 131, 66-68
72. Yu MK, Jeong YY, Park J, Park S, Kim JW, Min JJ, Kim K, Jon S. Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew. Chem. Int. Ed. Engl. 2008, 47, 5362-5365
73. Manzoor AA, Lindner LH, Landon CD, Park JY, Simnick AJ, Dreher MR, Das S, Hanna G, Park W, Chilkoti A, Koning GA, ten Hagen TL, Needham D, Dewhirst MW. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res. 2012, 72, 5566-5575
74. Ghosh S, Dutta S, Gomes E, Carroll D, D'Agostino R, Jr, Olson J, Guthold M, Gmeiner WH. Increased heating efficiency and selective thermal ablation of malignant tissue with DNA-encased multiwalled carbon nanotubes. ACS Nano 2009, 3, 2667-2673
75. Love SA, Maurer-Jones MA, Thompson JW, Lin YS, Haynes CL. Assessing nanoparticle toxicity. Annu. Rev. Anal. Chem. (Palo Alto Calif.) 2012, 5, 181-205
76. Elias DR, Poloukhtine A, Popik V, Tsourkas A. Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomedicine 2013, 9, 194-201
77. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 2013, 65, 71-79
78. Liu C, Liu F, Feng L, Li M, Zhang J, Zhang N. The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles. Biomaterials 2013, 34, 2547-2564
79. Stern ST, McNeil SE. Nanotechnology safety concerns revisited. Toxicol. Sci. 2008, 101, 4-21
80. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond.) 2007, 2, 415-423
81. Zhang C, Awasthi N, Schwarz MA, Hinz S, Schwarz RE. Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. PLoS One 2013, 8, e58037
82. Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Blood 2012, 119, 3561-3570
83. Brewer S, Nair-Gill E, Wei B, Chen L, Li X, Riedinger M, Campbell DO, Wiltzius S, Satyamurthy N, Phelps ME, Radu C, Witte ON, Braun J. Epithelial uptake of [18F]1-(2'-deoxy-2'-arabinofuranosyl) cytosine indicates intestinal inflammation in mice. Gastroenterology 2010, 138, 1266-1275
84. Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, Witte ON, Satyamurthy N, Czernin J, Schiepers C. Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway. Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 711-721
85. Boles KS, Schmieder AH, Koch AW, Carano RA, Wu Y, Caruthers SD, Tong RK, Stawicki S, Hu G, Scott MJ, Zhang H, Reynolds BA, Wickline SA, Lanza GM. MR angiogenesis imaging with Robo4-vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J. 2010, 24, 4262-4270
86. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang H, Robertson JD, Wickline SA, Lanza GM. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 2003, 63, 5838-5843
87. Castro JE, Melo-Cardenas J, Urquiza M, Barajas-Gamboa JS, Pakbaz RS, Kipps TJ. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res. 2012, 72, 2937-2948
88. Bartlett DW, Davis ME. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng. 2008, 99, 975-985
89. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464, 1067-1070
90. Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. USA 2007, 104, 5715-5721
91. Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, Davis ME. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res. 2006, 12, 1606-1614
92. Ghazani AA, McDermott S, Pectasides M, Sebas M, Mino-Kenudson M, Lee H, Weissleder R, Castro CM. Comparison of select cancer biomarkers in human circulating and bulk tumor cells using magnetic nanoparticles and a miniaturized micro-NMR system. Nanomedicine: NBM 2013;xx:1-9, doi: 10.1016/j.nano.2013.03.011
93. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn. J. Clin. Oncol. 2010, 40, 107-111
94. Veltri A, Guarnieri T, Gazzera C, Busso M, Solitro F, Fora G, Racca P. Long-term outcome of radiofrequency thermal ablation (RFA) of liver metastases from colorectal cancer (CRC): size as the leading prognostic factor for survival. Radiol. Med. 2012, 117, 1139-1151
95. Mylona S, Stroumpouli E, Pomoni M, Galani P, Ntai S, Thanos L. Radiofrequency ablation of liver metastases from cancer of unknown primary site. Diagn. Interv. Radiol. 2009, 15, 297-302
96. Vogl TJ, Naguib NN, Nour-Eldin NE, Mack MG, Zangos S, Abskharon JE, Jost A. Repeated chemoembolization followed by laser-induced thermotherapy for liver metastasis of breast cancer. AJR Am. J. Roentgenol. 2011, 196, W66-W72
97. Vogl TJ, Naguib NN, Gruber-Rouh T, Koitka K, Lehnert T, Nour-Eldin NE. Microwave ablation therapy: clinical utility in treatment of pulmonary metastases. Radiology 2011, 261, 643-651
98. Lo SS, Moffatt-Bruce SD, Dawson LA, Schwarz RE, Teh BS, Mayr NA, Lu JJ, Grecula JC, Olencki TE, Timmerman RD. The role of local therapy in the management of lung and liver oligometastases. Nat. Rev. Clin. Oncol. 2011, 8, 405-416
99. Zheng Y, Fernando HC. Surgical and nonresectional therapies for pulmonary metastasis. Surg. Clin. North Am. 2010, 90, 1041-1051
100. Mayo SC, Pawlik TM. Thermal ablative therapies for secondary hepatic malignancies. Cancer J. 2010, 16, 111-117
101. Cornelis F, Balageas P, Le Bras Y, Rigou G, Boutault JR, Bouzgarrou M, Grenier N. Radiologically-guided thermal ablation of renal tumours. Diagn. Interv. Imaging 2012, 93, 246-261
102. Lorentzen T, Skjoldbye BO, Nolsoe CP. Microwave ablation of liver metastases guided by contrast-enhanced ultrasound: experience with 125 metastases in 39 patients. Ultraschall Med. 2011, 32, 492-496
103. Vogl TJ, Farshid P, Naguib NN, Zangos S. Thermal ablation therapies in patients with breast cancer liver metastases: a review. Eur. Radiol. 2013, 23, 797-804
104. Munireddy S, Katz S, Somasundar P, Espat NJ. Thermal tumor ablation therapy for colorectal cancer hepatic metastasis. J. Gastrointest. Oncol. 2012, 3, 69-77
105. Mues AC, Mucksavage P, Graversen JA, Landman J. BioGlue surgical adhesive as a thermal reflector during laparoscopic cryoablation: effect on iceball size and ablation zone diameter. JSLS 2012, 16, 23-26
106. Kawaguchi M, Ohno J, Irie A, Fukushima T, Yamazaki J, Nakashima N. Dispersion stability and exothermic properties of DNA-functionalized single-walled carbon nanotubes. Int. J. Nanomed. 2011, 6, 729-736
107. Kawaguchi M, Yamazaki J, Ohno J, Fukushima T. Preparation and binding study of a complex made of DNA-treated singlewalled carbon nanotubes and antibody for specific delivery of a "molecular heater" platform. Int. J. Nanomed. 2012, 7, 4363-4371
108. Bozzini G, Colin P, Nevoux P, Villers A, Mordon S, Betrouni N. Focal therapy of prostate cancer: energies and procedures. Urol. Oncol. 2013, 31, 155-167
109. Haen SP, Pereira PL, Salih HR, Rammensee HG, Gouttefangeas C. More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin. Dev. Immunol. 2011, 2011, 160250
110. Bader MJ, Stepp H, Beyer W, Pongratz T, Sroka R, Kriegmair M, Zaak D, Welschof M, Tilki D, Stief CG, Waidelich R. Photodynamic therapy of bladder cancer-a phase I Study Using Hexaminolevulinate (HAL). Urol Oncol. 2012. Doi:10.1016/j.urolonc.2012.02.007
111. Lindenmann J, Matzi V, Neuboeck N, Anegg U, Baumgartner E, Maier A, Smolle J, Smolle-Juettner FM. Individualized, multimodal palliative treatment of inoperable esophageal cancer: clinical impact of photodynamic therapy resulting in prolonged survival. Lasers Surg. Med. 2012, 44, 189-198
112. Sawa M, Iwata E, Ishikawa K, Gomi F, Nishida K, Terasaki H. Comparison of different treatment intervals between bevacizumab injection and photodynamic therapy in combined therapy for age-related macular degeneration. Jpn. J. Ophthalmol. 2012, 56, 470-475
113. Ethirajan M, Chen Y, Joshi P, Pandey RK. The role of porphyrin chemistry in tumor imaging and photodynamic therapy. Chem. Soc. Rev. 2010, 40, 340-362
114. Chin WW, Heng PW, Thong PS, Bhuvaneswari R, Hirt W, Kuenzel S, Soo KC, Olivo M. Improved formulation of photosensitizer chlorin e6 polyvinylpyrrolidone for fluorescence diagnostic imaging and photodynamic therapy of human cancer. Eur. J. Pharm. Biopharm. 2008, 69, 1083-1093
115. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006, 312, 1027-1030
116. Wang Z, Liu H, Yang SH, Wang T, Liu C, Cao YC. Nanoparticlebased artificial RNA silencing machinery for antiviral therapy. Proc. Natl. Acad. Sci. USA 2012, 109, 12387-12392
117. Fabbro C, Ali-Boucetta H, Da Ros T, Kostarelos K, Bianco A, Prato M. Targeting carbon nanotubes against cancer. Chem. Commun. (Camb.) 2012, 48, 3911-3926
118. Gerweck LE. Modification of cell lethality at elevated temperatures. The pH effect. Radiat. Res. 1977, 70, 224-235
119. Dewey WF, Freeman ML, Raaphorst GP. Cellular biology of hyperthermia and radiation. In Radiation Biology in Cancer Research, Series: M. D. Anderson Symposia on Fundamental Cancer Research, 32nd. Raymond E. Meyn and H. Rodney Withers, Eds., Raven Press: New York, 1980
120. Szlachcic A, Pala K, Zakrzewska M, Jakimowicz P, Wiedlocha A, Otlewski J. FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int. J. Nanomed. 2012, 7, 5915-5927
121. You J, Zhang R, Xiong C, Zhong M, Melancon M, Gupta S, Nick AM, Sood AK, Li C. Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res. 2012, 72, 4777-4786
122. Silva AC, Oliveira TR, Mamani JB, Malheiros SM, Malavolta L, Pavon LF, Sibov TT, Amaro E, Jr, Tannus A, Vidoto EL, Martins MJ, Santos RS, Gamarra LF. Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment. Int. J. Nanomed. 2011, 6, 591-603
123. Grull H, Langereis S. Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound. J. Control. Release 2012, 161, 317-327
124. Krishnan KM. Biomedical nanomagnetics: a spin through possibilities in imaging, diagnostics, and therapy. IEEE Trans. Magn. 2010, 46, 2523-2558
125. Buzea C, Pacheco II, Robbie K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases 2007, 2, MR17-MR71
126. Zern BJ, Chacko AM, Liu J, Greineder CF, Blankemeyer ER, Radhakrishnan R, Muzykantov V. Reduction of nanoparticle avidity enhances the selectivity of vascular targeting and PET detection of pulmonary inflammation. ACS Nano 2013, 7, 2461-2469
127. Kettering M, Winter J, Zeisberger M, Alexiou C, Bremer-Streck S, Bergemann C, Kaiser WA, Hilger I. Magnetically based enhancement of nanoparticle uptake in tumor cells: combination of magnetically induced cell labeling and magnetic heating. Rofo 2006, 178, 1255-1260
128. Huang XL, Zhang B, Ren L, Ye SF, Sun LP, Zhang QQ, Tan MC, Chow GM. In vivo toxic studies and biodistribution of near infrared sensitive Au-Au(2)S nanoparticles as potential drug delivery carriers. J. Mater. Sci. Mater. Med. 2008, 19, 2581-2588
129. Kim J, Piao Y, Hyeon T. Multifunctional nanostructured materials for multimodal imaging, and simultaneous imaging and therapy. Chem. Soc. Rev. 2009, 38, 372-390.